{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:46:10Z","timestamp":1791805570266,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adherent-invasive\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    (AIEC) is implicated in Crohn\u2019s disease (CD) pathogenesis, but whether fecal microbiota transplantation (FMT) clears mucosal AIEC and alters fecal and mucosal microbiomes has not been studied. In this open-label pilot study, thirty adults with CD and seropositivity for serum anti-\n                    <jats:italic>E.coli<\/jats:italic>\n                    antibody (AEcAb) received a single colonoscopic FMT from one of two donors (ClinicalTrials.gov identifier NCT05611866). The primary outcome was adverse events (AEs) within 12 weeks after FMT; secondary outcomes included changes in mucosal AIEC, clinical measures, and fecal and mucosal microbiome profiles. Shotgun metagenomic sequencing for fecal samples and 16S rRNA sequencing for ileal mucosal samples were performed at baseline and after FMT. Baseline AEcAb levels were higher in patients with mucosal AIEC colonization (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.019) and remained elevated after FMT. No FMT-related serious adverse events were reported. FMT was associated with mucosal AIEC decolonization in all 8 evaluable baseline-positive patients. Mucosal alpha diversity increased after FMT (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.023), which correlated with reduced fecal calprotectin (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.034). Microbial pathway profiles in CD patients resembled those of their respective donors with reduced donor-recipient dissimilarity post-FMT (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.030), particularly among recipients with mucosal AIEC decolonization (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.039). In conclusion, this open-label pilot study demonstrates the feasibility of FMT for modulating mucosal AIEC colonization in CD and highlights the importance of capturing microbial changes at the disease site that may be undetectable in fecal samples.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-77455-7","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:53:07Z","timestamp":1789041187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fecal microbiota transplantation for the decolonization of mucosal adherent-invasive Escherichia coli in Crohn\u2019s disease: an open-label pilot study"],"prefix":"10.1038","volume":"17","author":[{"given":"Zhilu","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8653-0365","authenticated-orcid":false,"given":"Tingting","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid N.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc T. L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce W. Y.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K. L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Chevarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Buisson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-4454","authenticated-orcid":false,"given":"Siew C.","family":"NG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"77455_CR1","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres, J., Mehandru, S., Colombel, J. F. & Peyrin-Biroulet, L. Crohn\u2019s disease. Lancet 389, 1741\u20131755 (2017).","journal-title":"Lancet"},{"key":"77455_CR2","doi-asserted-by":"publisher","first-page":"jjaf042","DOI":"10.1093\/ecco-jcc\/jjaf042","volume":"19","author":"T Chhibba","year":"2025","unstructured":"Chhibba, T. et al. Environmental risk factors of inflammatory bowel disease: toward a strategy of preventative health. J. Crohns Colitis 19, jjaf042 (2025).","journal-title":"J. Crohns Colitis"},{"key":"77455_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/ng.3359","volume":"47","author":"JZ Liu","year":"2015","unstructured":"Liu, J. Z. et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47, 979\u2013986 (2015).","journal-title":"Nat. Genet."},{"key":"77455_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price, J. et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature 569, 655\u2013662 (2019).","journal-title":"Nature"},{"key":"77455_CR5","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng, S. C. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390, 2769\u20132778 (2017).","journal-title":"Lancet"},{"key":"77455_CR6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1053\/j.gastro.2019.11.294","volume":"158","author":"R Pittayanon","year":"2020","unstructured":"Pittayanon, R. et al. Differences in gut microbiota in patients with vs without inflammatory bowel diseases: a systematic review. Gastroenterology 158, 930\u2013946.e931 (2020).","journal-title":"Gastroenterology"},{"key":"77455_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1136\/gutjnl-2017-314903","volume":"67","author":"C Palmela","year":"2018","unstructured":"Palmela, C. et al. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut. 67, 574\u2013587 (2018).","journal-title":"Gut."},{"key":"77455_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1053\/j.gastro.2004.04.061","volume":"127","author":"A Darfeuille-Michaud","year":"2004","unstructured":"Darfeuille-Michaud, A. et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn\u2019s disease. Gastroenterology 127, 412\u2013421 (2004).","journal-title":"Gastroenterology"},{"key":"77455_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2587402","volume":"17","author":"E Bruder","year":"2025","unstructured":"Bruder, E. et al. Persistence mechanisms of Crohn\u2019s disease-associated adherent invasive Escherichia coli within macrophages. Gut Microbes 17, 2587402 (2025).","journal-title":"Gut Microbes"},{"key":"77455_CR10","doi-asserted-by":"publisher","first-page":"eaaf9655","DOI":"10.1126\/scitranslmed.aaf9655","volume":"9","author":"M Viladomiu","year":"2017","unstructured":"Viladomiu, M. et al. IgA-coated E. coli enriched in Crohn\u2019s disease spondyloarthritis promotes T(H)17-dependent inflammation. Sci. Transl. Med. 9, eaaf9655 (2017).","journal-title":"Sci. Transl. Med."},{"key":"77455_CR11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1136\/gutjnl-2013-304909","volume":"63","author":"B Chassaing","year":"2014","unstructured":"Chassaing, B., Koren, O., Carvalho, F. A., Ley, R. E. & Gewirtz, A. T. AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition. Gut. 63, 1069\u20131080 (2014).","journal-title":"Gut."},{"key":"77455_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2021.1994833","volume":"13","author":"X Zhilu","year":"2021","unstructured":"Zhilu, X. et al. Association of adherent-invasive Escherichia coli with severe gut mucosal dysbiosis in the Hong Kong Chinese population with Crohn\u2019s disease. Gut Microbes 13, 1994833 (2021).","journal-title":"Gut Microbes"},{"key":"77455_CR13","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1084\/jem.20090741","volume":"206","author":"FA Carvalho","year":"2009","unstructured":"Carvalho, F. A. et al. Crohn\u2019s disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J. Exp. Med. 206, 2179\u20132189 (2009).","journal-title":"J. Exp. Med."},{"key":"77455_CR14","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/ibd\/izy386","volume":"25","author":"JM Schmitz","year":"2019","unstructured":"Schmitz, J. M. et al. Murine adherent and Invasive E. coli induces chronic inflammation and immune responses in the small and large intestines of mono-associated IL-10-\/- Mice independent of long polar fimbriae adhesin A. Inflamm. Bowel Dis. 25, 875\u2013885 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"77455_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100642","volume":"29-30","author":"SMD Baunwall","year":"2020","unstructured":"Baunwall, S. M. D. et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis. EClinicalMedicine 29-30, 100642 (2020).","journal-title":"EClinicalMedicine"},{"key":"77455_CR16","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1136\/gutjnl-2023-329948","volume":"72","author":"LR Lopetuso","year":"2023","unstructured":"Lopetuso, L. R. et al. The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease. Gut. 72, 1642\u20131650 (2023).","journal-title":"Gut."},{"key":"77455_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","volume":"166","author":"AF Peery","year":"2024","unstructured":"Peery, A. F. et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology 166, 409\u2013434 (2024).","journal-title":"Gastroenterology"},{"key":"77455_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1001\/jama.2018.20046","volume":"321","author":"SP Costello","year":"2019","unstructured":"Costello, S. P. et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: a randomized clinical trial. JAMA 321, 156\u2013164 (2019).","journal-title":"JAMA"},{"key":"77455_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s00384-023-04354-4","volume":"38","author":"S Zhou","year":"2023","unstructured":"Zhou, S., Cui, Y., Zhang, Y., Zhao, T. & Cong, J. Fecal microbiota transplantation for induction of remission in Crohn\u2019s disease: a systematic review and meta-analysis. Int J. Colorectal Dis. 38, 62 (2023).","journal-title":"Int J. Colorectal Dis."},{"key":"77455_CR20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S2468-1253(22)00170-4","volume":"7","author":"H Tian","year":"2022","unstructured":"Tian, H., Zhang, S., Qin, H., Li, N. & Chen, Q. Long-term safety of fecal microbiota transplantation for gastrointestinal diseases in China. Lancet Gastroenterol. Hepatol. 7, 702\u2013703 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"77455_CR21","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.14309\/ajg.0000000000003196","volume":"120","author":"D Kao","year":"2024","unstructured":"Kao, D. et al. Preliminary results from a multicenter, randomized trial using fecal microbiota transplantation to induce remission in patients with mild-to-moderate Crohn\u2019s disease. Am. J. Gastroenterol. 120, 1334\u20131344 (2024).","journal-title":"Am. J. Gastroenterol."},{"key":"77455_CR22","doi-asserted-by":"publisher","unstructured":"Liu, C. S. et al. Towards optimising and standardising donor screening for fecal microbiota transplantation. Gut https:\/\/doi.org\/10.1136\/gutjnl-2025-336532 (2025).","DOI":"10.1136\/gutjnl-2025-336532"},{"key":"77455_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nature13828","volume":"517","author":"CG Buffie","year":"2015","unstructured":"Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid-mediated resistance to Clostridium difficile. Nature 517, 205\u2013208 (2015).","journal-title":"Nature"},{"key":"77455_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2281011","volume":"15","author":"SA Hamed","year":"2023","unstructured":"Hamed, S. A. et al. Butyrate reduces adherent-invasive E. coli-evoked disruption of epithelial mitochondrial morphology and barrier function: involvement of free fatty acid receptor 3. Gut Microbes 15, 2281011 (2023).","journal-title":"Gut Microbes"},{"key":"77455_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/nature09415","volume":"467","author":"SE Winter","year":"2010","unstructured":"Winter, S. E. et al. Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature 467, 426\u2013429 (2010).","journal-title":"Nature"},{"key":"77455_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2333483","volume":"16","author":"IA Sheikh","year":"2024","unstructured":"Sheikh, I. A. et al. Transplant of microbiota from Crohn\u2019s disease patients to germ-free mice results in colitis. Gut Microbes 16, 2333483 (2024).","journal-title":"Gut Microbes"},{"key":"77455_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-017-0490-5","volume":"9","author":"AB Hall","year":"2017","unstructured":"Hall, A. B. et al. A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients. Genome Med. 9, 103 (2017).","journal-title":"Genome Med."},{"key":"77455_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112568","volume":"28","author":"Y Dang","year":"2025","unstructured":"Dang, Y. et al. Gut microbiome signatures predict 5-ASA efficacy in ulcerative colitis. iScience 28, 112568 (2025).","journal-title":"iScience"},{"key":"77455_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42788-0","volume":"14","author":"L Ning","year":"2023","unstructured":"Ning, L. et al. Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts. Nat. Commun. 14, 7135 (2023).","journal-title":"Nat. Commun."},{"key":"77455_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112120","volume":"42","author":"J Sohn","year":"2023","unstructured":"Sohn, J. et al. Periodontal disease is associated with increased gut colonization of pathogenic Haemophilus parainfluenzae in patients with Crohn\u2019s disease. Cell Rep. 42, 112120 (2023).","journal-title":"Cell Rep."},{"key":"77455_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature11225","volume":"487","author":"S Devkota","year":"2012","unstructured":"Devkota, S. et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10\u2212\/\u2212 mice. Nature 487, 104\u2013108 (2012).","journal-title":"Nature"},{"key":"77455_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.4","volume":"2","author":"J Halfvarson","year":"2017","unstructured":"Halfvarson, J. et al. Dynamics of the human gut microbiome in inflammatory bowel disease. Nat. Microbiol 2, 17004 (2017).","journal-title":"Nat. Microbiol"},{"key":"77455_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45855-2","volume":"15","author":"S Hu","year":"2024","unstructured":"Hu, S. et al. Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease. Nat. Commun. 15, 1470 (2024).","journal-title":"Nat. Commun."},{"key":"77455_CR34","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/s41591-025-04186-5","volume":"32","author":"S Duttagupta","year":"2026","unstructured":"Duttagupta, S. et al. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Nat Med. 32, 1337\u20131350 (2026).","journal-title":"Nat Med."},{"key":"77455_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ueg2.12161","volume":"9","author":"A Buisson","year":"2021","unstructured":"Buisson, A. et al. Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive E. coli in Crohn\u2019s disease. U. Eur. Gastroenterol. J. 9, 1007\u20131018 (2021).","journal-title":"U. Eur. Gastroenterol. J."},{"key":"77455_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/j.0105-2896.2006.00402.x","volume":"211","author":"RM Zinkernagel","year":"2006","unstructured":"Zinkernagel, R. M. & Hengartner, H. Protective \u2018immunity\u2019 by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called \u2018immunological memory. Immunol. Rev. 211, 310\u2013319 (2006).","journal-title":"Immunol. Rev."},{"key":"77455_CR37","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41591-022-01964-3","volume":"28","author":"G Ianiro","year":"2022","unstructured":"Ianiro, G. et al. Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. Nat. Med. 28, 1913\u20131923 (2022).","journal-title":"Nat. Med."},{"key":"77455_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100711","volume":"3","author":"D Podlesny","year":"2022","unstructured":"Podlesny, D. et al. Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics. Cell Rep. Med. 3, 100711 (2022).","journal-title":"Cell Rep. Med."},{"key":"77455_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2600055","volume":"17","author":"D Zhao","year":"2025","unstructured":"Zhao, D. et al. Recipients\u2019 native bacteria determine the outcome of FMT treatment in inflammatory bowel disease. Gut Microbes 17, 2600055 (2025).","journal-title":"Gut Microbes"},{"key":"77455_CR40","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.tim.2016.02.002","volume":"24","author":"A Moya","year":"2016","unstructured":"Moya, A. & Ferrer, M. Functional redundancy-induced stability of gut microbiota subjected to disturbance. Trends Microbiol. 24, 402\u2013413 (2016).","journal-title":"Trends Microbiol."},{"key":"77455_CR41","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1136\/gutjnl-2015-311059","volume":"66","author":"CL O\u2019Brien","year":"2017","unstructured":"O\u2019Brien, C. L. et al. Comparative genomics of Crohn\u2019s disease-associated adherent-invasive Escherichia coli. Gut. 66, 1382\u20131389 (2017).","journal-title":"Gut."},{"key":"77455_CR42","doi-asserted-by":"publisher","first-page":"e1009581","DOI":"10.1371\/journal.pcbi.1009581","volume":"17","author":"MS Robeson","year":"2021","unstructured":"Robeson, M. S. et al. RESCRIPt: reproducible sequence taxonomy reference database management. PLoS Comput. Biol. 17, e1009581 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"77455_CR43","doi-asserted-by":"publisher","first-page":"e1006102","DOI":"10.1371\/journal.pcbi.1006102","volume":"14","author":"SM Gibbons","year":"2018","unstructured":"Gibbons, S. M., Duvallet, C. & Alm, E. J. Correcting for batch effects in case-control microbiome studies. PLoS Comput. Biol. 14, e1006102 (2018).","journal-title":"PLoS Comput. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77455-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77455-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77455-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:03:11Z","timestamp":1791802991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77455-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77455"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77455-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.C.N. has served as an advisory board member for Pfizer, Ferring, Janssen and Abbvie and received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie and Takeda; has received research grants through her affiliated institutions from Olympus, Ferring and Abbvie; is a founder member, non-executive director, non-executive scientific advisor and shareholder of GenieBiome Ltd which is non-remunerative; is a shareholder of MicroSigX Diagnostic Holding Limited; is a founder member, non-executive Board Director, and non-executive scientific advisor of MicroSigX Biotech Diagnostic Limited, which is non-remunerative; and receives patent royalties through her affiliated institutions. F.K.L.C. serves as the Principal Investigator for the Fecal Microbiota Transplantation Service under the Hospital Authority (HA). He is a Board Director of EHealth Plus Digital Technology Ltd., an HA-owned subsidiary driving the eHealth+ program to transform the Electronic Health Record Sharing System into a comprehensive digital healthcare platform and advance other IT initiatives within the eHealth ecosystem. Additionally, he is a Board Director of CUHK Medical Services Limited. F.K.L.C. is a shareholder of GenieBiome Holdings Limited and the co-founder, non-executive Board Chairman, and non-executive Scientific Advisor of its wholly owned subsidiary, GenieBiome Ltd. He is a shareholder of MicroSigX Diagnostic Holding Limited and the co-founder, non-executive Board Chairman, and non-executive Scientific Advisor of its wholly owned subsidiary, MicroSigX Biotech Diagnostic Limited. He also serves as a Director of the Hong Kong Investment Corporation Limited and a member of the Steering Committee for the RAISe+ Scheme under the Innovation and Technology Commission. Furthermore, he is the Co-Director of the Microbiota I-Center (MagIC) Ltd. FKLC receives advisory fees and speaker honoraria from AstraZeneca and Comvita New Zealand Limited, as well as patent royalties through affiliated institutions for microbiome-related applications. S.C.N., Z.X., and F.K.L.C. are named inventors of patent applications held by the CUHK and MagIC that cover the therapeutic and diagnostic use of the microbiome. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10678"}}